Principia Biopharma

Sanofi reports setbacks to Denali, Kymab and Principia assets, delivering mix of misses and halts
Fierce Biotech
Fri, 10/27/23 - 11:36 am
Sanofi
Denali
Kymab
Principia Biopharma
Sanofi, after $8B outlay, sees M&A strategy deliver 2 more duds
Fierce Biotech
Thu, 04/27/23 - 11:40 am
Sanofi
M&A
earnings
Ablynx
Principia Biopharma
Sanofi’s Principia purchase fails its first test
EP Vantage
Thu, 09/9/21 - 10:53 am
Sanofi
rilzabrutinib
Principia Biopharma
clinical trials
pemphigus vulgaris
The top 10 largest biopharma M&A deals in 2020
Fierce Pharma
Tue, 01/19/21 - 10:30 am
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Gilead Sciences
Forty Seven
Merck
VelosBio
Nestle
Aimmune
Immunomedics
JNJ
Momenta Pharmaceuticals
Sanofi
Principia Biopharma
Bayer
Asklepios BioPharmaeutical
The top 5 pharma M&A deals of 2020
Pharmaforum
Mon, 12/21/20 - 11:07 am
M&A
AstraZeneca
Alexion
Gilead Sciences
Immunomedics
Forty Seven
JNJ
Momenta
Sanofi
Principia Biopharma
Rilzabrutinib granted FDA fast track designation for treatment of immune thrombocytopenia
Pharmaceutical Business Review
Thu, 11/19/20 - 10:40 am
rilzabrutinib
fast track
FDA
Sanofi
Principia Biopharma
chronic immune thrombocytopenia
Gilead rescues biopharma’s takeout scene
EP Vantage
Wed, 10/7/20 - 11:02 am
M&A
Gilead Sciences
Immunomedics
JNJ
Momenta Pharmaceuticals
Sanofi
Principia Biopharma
Nestle
Aimmune
Tizona Therapeutics
Sanofi, seeking control of key drug, to buy Principia for $3.7B
BioPharma Dive
Mon, 08/17/20 - 01:03 pm
Sanofi
Principia Biopharma
M&A
multiple sclerosis
MS
SAR442168
Sanofi has a $50B biotech buyout budget, with Principia top of the list: report
Fierce Biotech
Fri, 07/17/20 - 11:02 am
Sanofi
M&A
Principia Biopharma
Sanofi posts data from contentious phase 2 multiple sclerosis trial
Fierce Biotech
Thu, 04/23/20 - 09:15 pm
Sanofi
clinical trials
MS
multiple sclerosis
Principia Biopharma
SAR442168
Multiple sclerosis “win” makes the Principia shorts squirm
EP Vantage
Thu, 02/6/20 - 10:51 am
Principia Biopharma
SAR442168
MS
multiple sclerosis
Adrangi mounts short attack on 'worthless' drugs of Sanofi ally
Fierce Biotech
Tue, 01/28/20 - 11:07 am
Principia Biopharma
Sanofi
autoimmune disease
Kerrisdale Capital
Ex-AbbVie partner Principia posts encouraging PhII results for its BTK-inhibitor
Endpoints
Fri, 10/11/19 - 10:40 am
AbbVie
Principia Biopharma
PRN1008
pemphigus vulgaris
Principia, AbbVie walk away from 2017 partnership for inflammatory, autoimmune drugs
Endpoints
Mon, 03/11/19 - 10:38 am
AbbVie
Principia Biopharma
inflammatory diseases
autoimmune disease
Principia jumps after $106.3M IPO
BioCentury
Fri, 09/14/18 - 11:39 pm
Principia Biopharma
IPOs
Principia Sets IPO Terms as It Eyes Late-Stage Studies for Lead Drug
Xconomy
Tue, 09/4/18 - 11:06 pm
Principia Biopharma
IPOs
AbbVie, Sanofi-backed Principia offers an $86M IPO after burning through $148M for pipeline work
Endpoints
Mon, 08/20/18 - 10:11 am
IPOs
Principia Biopharma
Sanofi
AbbVie
PRN1008
autoimmune disease
Sanofi bolsters its position on multiple sclerosis with a $765M BTK licensing deal
Endpoints
Thu, 11/9/17 - 12:02 pm
Sanofi
multiple sclerosis
MS
Principia Biopharma